Saturday 17 October 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.26
0.03
−2.33%
Follow NBP
| Jun '26 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | (18.46%) | (4.12%) |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | (17.37%) | (2.61%) | ||
ROIC |
0.00% | 0.00% | (76.65%) | (101.34%) | |
Return on Tangible Assets |
0.00% | 0.00% | (24.92%) | (5.47%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | (1.39) | 0.00 | |
Free Cash Flow |
(92.64) | (108.70) | (113.36) | — | |
Capital Expenditures |
(1.04) | 0.11 | (2.71) | — | |
| Other line items | |||||
Cash ROIC |
(23.64%) | (22.31%) | (31.29%) | 0.00% | |
Tax Rate |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Operating CF/Net income |
0.00 | 0.00 | 2.77 | 0.00 | |
Depreciation/Fixed assets |
1.29 | 10.32 | 11.46 | 0.00 | |
Capex/Depreciation |
(0.64) | 0.07 | (1.38) | — | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (1.35) | 0.00 | |
Capex per Share |
0.00 | 0.00 | (0.03) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 1 Oct 2026